SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Shares of Theratechnologies (NASDAQ:THTX) spiked on Wednesday after the FDA approved a new formulation of its bestselling ...

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 ...

Supporters say consumers should be protected from unknowingly eating material from novel vaccines, which are similar to COVID ...

This came as part of the continuous regulatory surveillance, where drug samples are picked from sales/distribution points, ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal ...

The Global Single-cell Analysis Market is projected to grow at a CAGR of 9.5% from 2026 to 2033, according to a new report published by Verified Market Reports ®. The report reveals that the market ...